fbpx
2-22-2021

DeepIntent CEO Chris Paquette Named to the MM+M 40 Under 40 Class of 2021

Paquette honored amongst the brightest young stars in the evolving and expanding realm of healthcare marketing

NEW YORK, February 22, 2021 – DeepIntent, the leading healthcare marketing technology company built purposefully to influence patient health and business outcomes, today announced that its Chief Executive Officer and Founder, Chris Paquette, has been named to the 2021 MM+M class of 40 Under 40 honorees. In its second year, the program shines a light on the young individuals whose leadership, thinking, and digital know-how have contributed to the industry’s continued growth under challenging market conditions.

“It’s an honor to be listed in the esteemed MM+M 40 Under 40 Awards,” said Chris Paquette, founder and chief executive officer, DeepIntent. “This achievement is dedicated to the entire DeepIntent team, our clients, and partners who have rallied behind me over the last five years to prove that marketing technology can measurably improve the lives of patients.”

This year’s 40 Under 40 list includes individuals who hail from pharma and biotech companies, medical marketing agencies, device manufacturers, analytics firms and health media. The honorees hold a range of essential account, strategy, creative and digital positions at those organizations. Through their continued efforts, they inspire confidence that the industry is in good hands for many years to come.

“When we started the 40 Under 40 program last year, we were blown away by the volume of smart young people doing high-caliber work,” said MM+M GM and editor-in-chief Steve Madden. “As they assume greater leadership roles, the industry should feel very secure about its fortunes in the years ahead.”

This year’s 40 Under 40 honorees hail from a range of the industry’s biggest and most well-respected organizations, including AbbVie, Klick Health, Bristol Myers Squibb and Ashfield MedComms. The 2021 class of MM+M’s 40 Under 40 will be celebrated at a virtual ceremony on March 25. Click here to see the entire list of honorees.

 

About DeepIntent
Conceived by former Memorial Sloan Kettering data scientists, DeepIntent connects healthcare companies with patients and providers across every device through unique data, media partnerships, and integrations. From campaign planning to audience targeting to measuring and optimization, DeepIntent is proven to increase script lift while improving patients’ quality of life. Its Healthcare Marketing Platform empowers marketers at seven of the top ten pharmaceutical companies and leading healthcare advertising agencies to positively influence health and business outcomes. For more information, visit DeepIntent.com or find us on Twitter, Facebook, or LinkedIn.

About MM+M
First published in 1966 as Medical Marketing & Media, MM+M is the media brand of record for
pharmaceutical marketing and commercialization, delivering the most balanced and relevant coverage of the growing industry. The title produces an essential mix of online breaking news and analysis combined with monthly print features — timely, objective, original editorial content for an executive audience of leaders and thinkers who work in pharma, medical device, diagnostics and greater healthcare marketing. MM+M also develops conferences and live and virtual events, and engineers the industry’s premier awards program, the MM+M Awards.

Press Contact
Finn Partners for DeepIntent
Brian Sinderson
deepintent@finnpartners.com
415-640-7547

More Insights

DeepIntent Expands Healthcare Marketplace By Integrating Major Supply Sources
5-18-2021

Partners with Magnite, Xandr, Pubmatic, and TripleLift; offers zero-fee trading for direct deals delivering higher yields and greater operational efficiency NEW YORK, May…

Read More
DeepIntent Launches DeepIntent Outcomes™
4-6-2021

Industry’s First Demand-Side Platform Integrated With Real-World Clinical Data to Increase Script Lift, Improving Business Outcomes for Healthcare Marketers Beta leading pharmaceutical brand experienced an…

Read More
DeepIntent Releases Consumer Survey Findings on Impact of Direct-to-Consumer Pharmaceutical Advertising
3-25-2021

Demonstrates gap between patients and providers about treatment options NEW YORK, March 25, 2021 – DeepIntent, the leading healthcare marketing technology company built purposefully to…

Read More
Subscribe to Our NewsletterJoin our mailing list to get the latest product updates, actionable insights, and resources for healthcare marketers and publishers.

By clicking ‘Submit’ you agree to our Terms and Privacy Policy